ArticleJournal of mid-life health
Levonorgestrel intrauterine system (Mirena): An emerging tool for conservative treatment of abnormal uterine bleeding.
Article in Journal of mid-life health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- The role of different LNG-IUS therapies in the management of adenomyosis: a systematic review and meta-analysis.Reproductive biology and endocrinology : RB&E · 2025Pooled it
- The gap between prevalence of primary dysmenorrhea and available treatment strategies.Reproduction & fertility · 2026Review
- Efficacy and Outcomes of the Hormone-Releasing Levonorgestrel-Intrauterine System for Adenomyosis Treatment.Cureus · 2025Article
- A Study of the Effect of the Levonorgestrel Intrauterine System on the Management of Abnormal Uterine Bleeding.Cureus · 2025Article
- Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers.Journal of the National Cancer Institute · 2025Article
- Risks of pelvic inflammatory disease and bacterial vaginosis in adenomyosis patients using levonorgestrel intrauterine device or oral norethindrone.Frontiers in endocrinology · 2025Article
- Levonorgestrel-releasing intrauterine device to treat abnormal uterine bleeding; not one treatment option fits all.Journal of the Turkish German Gynecological Association · 2023Article
- Does Timing of Levonorgestrel Insertion in Women with Abnormal Uterine Bleeding Affect its Expulsion and Bleeding Pattern? A Follow-Up Study.Journal of obstetrics and gynaecology of India · 2023Article
- Anticoagulant therapy for women: implications for menstruation, pregnancy, and lactation.Hematology. American Society of Hematology. Education Program · 2022Article
- Effectiveness of Levonorgestrel Releasing Intrauterine System in Perimenopausal Women with Heavy Menstrual Bleeding: A Prospective Study at a Teaching Hospital in India.Journal of menopausal medicine · 2022Article
- Introducing the hormonal Intrauterine Device in Madagascar, Nigeria, and Zambia: results from a pilot study.Reproductive health · 2022Article
- Evidence-Based Management of Uterine Fibroids With Botanical Drugs-A Review.Frontiers in pharmacology · 2022Review
- More than just contraception: the impact of the levonorgestrel-releasing intrauterine system on public health over 30 years.BMJ sexual & reproductive health · 2021Article
- The Progestin Revolution: progestins are arising as the dominant players in the tight interlink between contraceptives and bleeding control.Contraception and reproductive medicine · 2021Article
- Management of heavy menstrual bleeding on anticoagulation.Hematology. American Society of Hematology. Education Program · 2020Review
- Predictors of a Successful Bipolar Radiofrequency Endometrial Ablation.Geburtshilfe und Frauenheilkunde · 2019Article
- Is LNG-IUS the One-Stop Answer to AUB?Journal of obstetrics and gynaecology of India · 2018Article
- Evaluate the Effectiveness of Conservative Treatment for Menorrhagia in Women who were Admitted to the Shahid Sadoughi Hospital of Yazd-Iran in 2014-2015.International journal of biomedical science : IJBS · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo study the efficacy of levonorgestrel intrauterine system (LNG-IUS; Mirena) in conservative management of abnormal uterine bleeding (AUB). MATERIALS AND
methodsSeventy women between 30 and 55 years with AUB were included in a study conducted over a period of 3 years. Response was assessed monthly for first 4 months and then yearly for maximum 2 years.
resultsMirena caused a 80% decrease in median menstrual blood loss (MBL) at 4 months, 95% decrease in MBL by 1 year, and 100% decrease (amenorrhea) by 2 years. Mean hemoglobin (Hb) % showed a significant rise of 7.8% from baseline 4 months post Mirena insertion. Mirena acted as an effective contraceptive in women not using any other form of contraception. Hysterectomy could be avoided in most of the women.
conclusionMirena provides an incredible nonsurgical alternative in treatment of menorrhagia. Its effects are reversible and it is an excellent fertility-sparing device. It is also an effective contraceptive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.